|
| Drug |
Author |
Ref. | Year | Design | Outcomes of interest | Study N Design | Patients N | Results | P value |
NNT
(95% CI) | Bottom line |
| Intervention | Control | Odds Ratio (95% CI) |
|
| β-Blockers |
Arsenault et al. |
[43] |
2013 |
MA | POAF | 33 RCTs | 2294 | 2404 | 0.33 (0.26 to 0.43) | <0.00001 | 7 (6–8) | β- Blockers are beneficial |
| Stroke | 5 RCTs | 774 | 780 | 1.34 (0.46 to 3.93) | 0.59 | 81 (43−505) | No significant decrease in stroke |
| Mortality | 16 RCTs | 1329 | 1342 | 0.87 (0.34 to 2.22) | 0.70 | NA | No significant decrease in mortality |
| CV mortality | 11 RCTs | 1003 | 1008 | 0.98 (0.10 to 9.66) | 0.99 | NA | No significant decrease in CV mortality |
| Length of stay | 6 RCTs | 844 | 832 | −0.74 days (−1.48 to 0.00) | 0.049 | NA | Shorter length of stay |
|
Khan et al. | [46] | 2013 |
MA | POAF | 10 RCTs | 1280 | 1276 | 0.50 (0.36 to 0.69) | <0.001 | 8 (6–11) | β-Blockers are beneficial |
|
| Amiodarone |
Arsenault et al. |
[43] |
2013 |
MA | POAF | 33 RCTs | 2603 | 2799 | 0.43 (0.34 to 0.54) | <0.00001 | 8 (6–9) | Amiodarone is beneficial |
| Stroke | 14 RCTs | 1523 | 1564 | 0.60 (0.35 to 1.02) | 0.061 | NA | No significant decrease in stroke |
| Mortality | 23 RCTs | 2045 | 2132 | 1.08 (0.74 to 1.56) | 0.70 | NA | No significant decrease in mortality |
| CV mortality | 14 RCTs | 1262 | 1253 | 0.93 (0.46 to 1.86) | 0.83 | NA | No significant decrease in CV mortality |
| Length of stay | 20 RCTs | 1716 | 1781 | −0.95 days (−1.37 to −0.52) | 0.000013 | NA | Significant decrease in length of stay |
|
Chatterjee et al. |
[47] |
2013 |
MA | POAF (oral-only) | 8 RCTs | 961 | 945 | 0.59 (0.49 to 0.70) | <0.00001 | 8 (6–11) | Amiodarone is beneficial |
| POAF (iv.) | 15 RCTs | 1052 | 992 | 0.57 (0.48 to 0.75) | <0.00001 | 8 (6–10) | POAF independent with regard to the route, |
| POAF preop administration | 11 RCTs | 1146 | 1067 | 0.55 (0.46 to 0.65) | <0.00001 | 7 (5–8) | timing of drug adm., and duration of treatment |
| POAF postop administration | 12 RCTs | 867 | 850 | 0.50 (0.33 to 0.75) | 0.0009 | 9 (6–14) | |
|
| |
Arsenault et al. |
[43] |
2013 |
MA | POAF | 11 RCTs | 799 | 810 | 0.34 (0.26 to 0.43) | <0.00001 | 5 (4–6) | Sotalol is beneficial |
| Stroke | 1 RCT | 63 | 65 | 0.34 (0.01 to 8.47) | 0.51 | NA | No significant decrease in stroke |
| CV mortality | 7 RCTs | 475 | 489 | 0.0 (0.0 to 0.0) | <0.00001 | NA | No significant decrease in CV mortality |
| Length of stay | 7 RCTs | 455 | 456 | −0.39 days (−0.77 to −0.02) | 0.040 | NA | Shorter length of stay |
| Sotalol |
Kerin and Jacob |
[48] |
2011 |
MA | POAF (sotalol versus placebo) | 5 RCTs | 489 | 499 | 0.55 (0.45 to 0.67) | <0.001 | 6 (4–8) | Sotalol is beneficial |
| POAF (sotalol versus no treatment) | 6 RCTs | 304 | 311 | 0.33 (0.24 to 0.46) | <0.001 | 4 (3–5) | Shorter length of stay |
| POAF (sotalol versus β-blocker) | 6 RCTs | 488 | 555 | 0.60 (0.50 to 0.84) | <0.001 | 12 (8–28) | |
| POAF preop administration | 5 RCTs | 389 | 400 | 0.55 (0.45 to 0.68) | <0.001 | 4 (3–5) | |
| POAF postop administration | 6 RCTs | 404 | 410 | 0.39 (0.29 to 0.51) | <0.001 | 5 (3–5) | |
| Length of stay | 5 RCTs | 339 | 349 | −0.5 days (−1.06 to −0.05) | <0.072 | NA | |
|
